Intra-Cellular Therapies (ITCI) Expected to Announce Earnings on Thursday

Intra-Cellular Therapies (NASDAQ:ITCI) is expected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Intra-Cellular Therapies to post earnings of ($0.08) per share and revenue of $193.29 million for the quarter.

Intra-Cellular Therapies Trading Up 0.5 %

NASDAQ ITCI opened at $128.60 on Thursday. Intra-Cellular Therapies has a 1-year low of $62.78 and a 1-year high of $128.75. The company has a market cap of $13.67 billion, a price-to-earnings ratio of -147.81 and a beta of 0.72. The company has a 50 day moving average of $108.45 and a 200-day moving average of $89.01.

Analyst Upgrades and Downgrades

ITCI has been the subject of several research analyst reports. Leerink Partnrs downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and boosted their price objective for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Piper Sandler restated a “neutral” rating and set a $132.00 price objective (up from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Baird R W downgraded shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday, January 22nd. Nine analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $103.62.

Insider Buying and Selling

In related news, CEO Sharon Mates sold 51,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $91,834,228.20. The trade was a 4.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.60% of the stock is currently owned by insiders.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.